Hypopigmentation disorder
|
0.200 |
Biomarker
|
disease |
BEFREE |
Nicastrin Deficiency Induces Tyrosinase-Dependent Depigmentation and Skin Inflammation.
|
31437444 |
2020 |
Hypopigmentation disorder
|
0.200 |
Biomarker
|
disease |
BEFREE |
Therefore, the inhibition of tyrosinase is a primary hypopigmentation mechanism.
|
30907884 |
2019 |
Hypopigmentation disorder
|
0.200 |
Biomarker
|
disease |
BEFREE |
DNp73-induced depigmentation, Slug increase and changes in cell motility are recapitulated in neural crest-derived melanophores of Xenopus embryos, underscoring a previously unnoticed physiological role of tyrosinase as EMT inhibitor.
|
30445206 |
2019 |
Hypopigmentation disorder
|
0.200 |
Biomarker
|
disease |
BEFREE |
The inhibitors of tyrosinase are important for the treatment of skin diseases associated with hyper-pigmentation after UV exposure and application in cosmetics for whitening and depigmentation.
|
28478573 |
2018 |
Hypopigmentation disorder
|
0.200 |
Biomarker
|
disease |
BEFREE |
We have examined the biochemical basis of the RD-induced leukoderma by elucidating the metabolic fate of RD in the course of tyrosinase-catalyzed oxidation.
|
29439519 |
2018 |
Hypopigmentation disorder
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Especially, 4,5-DCQA has depigmentation activity through the inhibitory effect on cellular tyrosinase directly and binding effect on adenylyl cyclase, resulting in the downregulation of MITF protein, thereby reducing the expression of melanogenic enzymes.
|
30030001 |
2018 |
Hypopigmentation disorder
|
0.200 |
Biomarker
|
disease |
BEFREE |
4-n-butyl resorcinol (4-nBR) is a highly effective tyrosinase inhibitor, and can be used in cosmetic product for depigmentation purpose.
|
29990716 |
2018 |
Hypopigmentation disorder
|
0.200 |
Biomarker
|
disease |
BEFREE |
The synthesis of melanin is primarily influenced by tyrosinase (TYR), which has attracted interest as a target molecule for the regulation of pigmentation or depigmentation in skin.
|
29271951 |
2017 |
Hypopigmentation disorder
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Whereas, antroquinonol obviously ameliorated depigmentation of mice skin and resisted the reduction of hair follicle length, skin thickness, and tyrosinase expression induced by H<sub>2</sub>O<sub>2</sub>.
|
29456788 |
2017 |
Hypopigmentation disorder
|
0.200 |
Biomarker
|
disease |
BEFREE |
CYM upregulated <i>Mitf</i> and possibly activates tyrosinase enzyme, providing evidence for its possible use to promote melanogenesis and as a therapeutic agent against hypopigmentation disorders.
|
29359158 |
2017 |
Hypopigmentation disorder
|
0.200 |
Biomarker
|
disease |
BEFREE |
Tyrosinase catalyzes the key step of melanogenesis, dysfunction of tyrosinase leads to reduce melanin production which results in severe clinical and aesthetical problems of hypopigmentation.
|
28019642 |
2017 |
Hypopigmentation disorder
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these results suggest that LfB17‑34 induces melanogenesis in B16F10 cells primarily through increased tyrosinase expression and activity and that LfB17‑34 could be further developed for the treatment of hypopigmentation disorders.
|
28204812 |
2017 |
Hypopigmentation disorder
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Further, CNN showed a weak but significant direct inhibitory effect on the enzymatic activity of tyrosinase, suggesting one possible mechanism of hypopigmentation.
|
29045474 |
2017 |
Hypopigmentation disorder
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Semi-quantitative RT-PCR analysis showed that the depigmentation effect of mefenamic acid and nimesulide might be due to the inhibition of tyrosinase gene transcription.
|
21079976 |
2011 |
Hypopigmentation disorder
|
0.200 |
Biomarker
|
disease |
BEFREE |
The substantial reduction of SLC45A2 protein in the patient's melanocytes caused the mislocalization of tyrosinase from melanosomes to the plasma membrane and also led to the incorporation of tyrosinase into exosomes and secretion into the culture medium, explaining the hypopigmentation in OCA-4.
|
21677667 |
2011 |
Hypopigmentation disorder
|
0.200 |
Biomarker
|
disease |
BEFREE |
Taken together, CFAB is a unique reagent that primarily accelerates tyrosinase decrease by a mechanism that differs from those considered for other hypopigmentation reagents currently reported.
|
21410768 |
2011 |
Hypopigmentation disorder
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Yellow oculocutaneous albinism (OCA) that is caused by tyrosinase gene mutations shows two characteristics: extreme hypopigmentation at birth and the eventual development of yellow or blond hair.
|
10559577 |
1999 |
Hypopigmentation disorder
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We have shown previously that active immunization of mice against the melanocyte differentiation antigen, a tyrosinase-related protein (TRP) gp75(TRP-1) (the brown locus protein) expressed by melanomas, could induce tumor immunity and autoimmunity manifested as depigmentation.
|
10587362 |
1999 |
Hypopigmentation disorder
|
0.200 |
Biomarker
|
disease |
BEFREE |
Tyrosinase inhibition due to interaction of homocyst(e)ine with copper: the mechanism for reversible hypopigmentation in homocystinuria due to cystathionine beta-synthase deficiency.
|
7611281 |
1995 |
Hypopigmentation disorder
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Patients with the depigmentation disorder vitiligo lack the capacity to synthesize the melanins from L-tyrosine via the essential activity of tyrosinase.
|
8204666 |
1994 |
Hypopigmentation disorder
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A novel type I OCA phenotype in which hypopigmentation is related to local body temperature is associated with a missense substitution in tyrosinase, codon 422 CGG (Arg)----CAG (Gln).
|
1900309 |
1991 |
Hypopigmentation disorder
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Hairbulb tyrosinase activity and glutathione content, as well as urine cysteinyldopa excretion, were low in PWS individuals with and without hypopigmentation and did not separate these two groups.
|
3578281 |
1987 |
Hypopigmentation disorder
|
0.200 |
Biomarker
|
disease |
HPO |
|
|
|
Hypopigmentation disorder
|
0.200 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Hypopigmentation disorder
|
0.200 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|